Selinisol tablets: Demonstrated efficacy against multiple myeloma and various cancers

Selinexor is a revolutionary anti-cancer drug that has been approved for the treatment of relapsed/refractory multiple myeloma (RRMM) based on its excellent performance in multiple combination treatment regimens. For patients with late-stage relapse who are refractory to pentamethasone, the combination therapy of selinesol and dexamethasone has shown significant effects. At the same time, the triple therapy of selinesol, bortezomib, and dexamethasone also showed encouraging therapeutic effects in patients who had received at least one previous treatment.

Selinesol belongs to the innovative drug class of selective nuclear transport inhibitors (SINEs). It precisely inhibits the activity of protein XPO1 and destroys the transport and localization mechanism of key proteins inside cancer cells, thereby effectively interfering with the survival and proliferation processes of cancer cells. This unique mechanism of action helps significantly slow down tumor growth and even induces cancer cell death. In addition, selinesol has demonstrated potential in multiple mid-stage and late-stage clinical trials in multiple cancer indications with high needs and unmet treatment needs, such as endometrial cancer and myelofibrosis.

As a prescription drug, the use of selinexol must be strictly guided by a professional physician. Before starting treatment, the doctor will conduct a comprehensive assessment of the patient's overall health and develop a personalized treatment plan based on the patient's specific situation. During treatment, if any discomfort or abnormal symptoms occur, you should report it to your doctor immediately. Doctors will flexibly adjust drug dosages, optimize treatment plans or provide corresponding supportive treatment measures based on the patient's real-time feedback to ensure patient treatment safety and maximize the effect.